EB-treated MS rats showed substantially decreased Nrf2 and HO-1 levels in the CSF and homogenate of the rat brain compared to the vehicle, sham, and AKBA 100 mg/kg perse treatment group. This evidence concerns the gene NFE2L2 and myeloid sarcoma.